| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 7 | 2023 | 198 | 2.950 |
Why?
|
| Head and Neck Neoplasms | 12 | 2024 | 1063 | 2.170 |
Why?
|
| Carcinoma, Squamous Cell | 9 | 2023 | 1096 | 1.870 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2015 | 447 | 1.640 |
Why?
|
| Adaptor Proteins, Signal Transducing | 9 | 2020 | 313 | 1.570 |
Why?
|
| Saliva | 2 | 2021 | 123 | 1.420 |
Why?
|
| ErbB Receptors | 8 | 2020 | 500 | 1.400 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2022 | 31 | 0.960 |
Why?
|
| Papillomavirus Infections | 7 | 2024 | 261 | 0.940 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2015 | 287 | 0.940 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2022 | 67 | 0.920 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2020 | 470 | 0.870 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2023 | 47 | 0.860 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 55 | 0.850 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 33 | 0.790 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2021 | 71 | 0.770 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 415 | 0.760 |
Why?
|
| Drug Discovery | 3 | 2022 | 107 | 0.730 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2024 | 132 | 0.730 |
Why?
|
| Lung Neoplasms | 8 | 2017 | 2347 | 0.720 |
Why?
|
| Mutation | 6 | 2020 | 4132 | 0.700 |
Why?
|
| DNA, Neoplasm | 1 | 2020 | 268 | 0.700 |
Why?
|
| Genome, Mitochondrial | 1 | 2019 | 27 | 0.690 |
Why?
|
| DNA Methylation | 7 | 2020 | 657 | 0.660 |
Why?
|
| Heterografts | 2 | 2017 | 102 | 0.660 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2020 | 1265 | 0.660 |
Why?
|
| DNA, Mitochondrial | 1 | 2019 | 187 | 0.660 |
Why?
|
| Point Mutation | 1 | 2019 | 245 | 0.650 |
Why?
|
| Transforming Growth Factor beta | 3 | 2018 | 321 | 0.650 |
Why?
|
| Glutathione Transferase | 1 | 2019 | 112 | 0.640 |
Why?
|
| Biomarkers, Tumor | 6 | 2022 | 1543 | 0.630 |
Why?
|
| Receptor, Notch1 | 3 | 2020 | 94 | 0.630 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2018 | 616 | 0.610 |
Why?
|
| Adenocarcinoma | 2 | 2015 | 1194 | 0.610 |
Why?
|
| Papillomaviridae | 6 | 2022 | 156 | 0.600 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2015 | 96 | 0.570 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2019 | 121 | 0.570 |
Why?
|
| Humans | 57 | 2024 | 89073 | 0.550 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 164 | 0.530 |
Why?
|
| MicroRNAs | 3 | 2015 | 551 | 0.510 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2024 | 1363 | 0.500 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2013 | 125 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 5 | 2018 | 604 | 0.500 |
Why?
|
| Leukoplakia, Oral | 1 | 2014 | 12 | 0.490 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2022 | 161 | 0.490 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 412 | 0.480 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 67 | 0.480 |
Why?
|
| Signal Transduction | 10 | 2022 | 3374 | 0.470 |
Why?
|
| Neoplasms | 5 | 2023 | 3035 | 0.450 |
Why?
|
| DNA | 2 | 2019 | 1307 | 0.450 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 2012 | 16 | 0.430 |
Why?
|
| Exodeoxyribonucleases | 1 | 2012 | 17 | 0.430 |
Why?
|
| Animals | 23 | 2023 | 27324 | 0.420 |
Why?
|
| DNA Mismatch Repair | 1 | 2012 | 55 | 0.420 |
Why?
|
| DNA Repair Enzymes | 1 | 2012 | 55 | 0.410 |
Why?
|
| Neoplasm Invasiveness | 6 | 2021 | 576 | 0.400 |
Why?
|
| DNA, Viral | 2 | 2023 | 261 | 0.400 |
Why?
|
| Repressor Proteins | 4 | 2022 | 423 | 0.380 |
Why?
|
| Artificial Intelligence | 3 | 2023 | 322 | 0.370 |
Why?
|
| Histones | 3 | 2020 | 329 | 0.370 |
Why?
|
| Middle Aged | 19 | 2024 | 25865 | 0.370 |
Why?
|
| Mice | 16 | 2021 | 11742 | 0.360 |
Why?
|
| Fibroblasts | 2 | 2012 | 755 | 0.360 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2024 | 340 | 0.350 |
Why?
|
| Lung | 2 | 2015 | 1258 | 0.340 |
Why?
|
| Neoplastic Stem Cells | 3 | 2020 | 161 | 0.340 |
Why?
|
| Male | 22 | 2024 | 42254 | 0.340 |
Why?
|
| Cell Proliferation | 9 | 2020 | 1650 | 0.340 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2022 | 481 | 0.340 |
Why?
|
| Cell Line, Tumor | 11 | 2024 | 2553 | 0.330 |
Why?
|
| Female | 26 | 2024 | 46014 | 0.330 |
Why?
|
| Lymphatic Metastasis | 2 | 2021 | 502 | 0.320 |
Why?
|
| Carcinoma | 2 | 2022 | 443 | 0.320 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 2412 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2017 | 1114 | 0.280 |
Why?
|
| Quinolones | 2 | 2024 | 60 | 0.270 |
Why?
|
| Proteins | 2 | 2022 | 786 | 0.260 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2024 | 2552 | 0.260 |
Why?
|
| Epigenesis, Genetic | 5 | 2020 | 507 | 0.250 |
Why?
|
| Adult | 12 | 2024 | 26508 | 0.250 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 459 | 0.250 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2021 | 887 | 0.240 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2020 | 395 | 0.230 |
Why?
|
| Cisplatin | 2 | 2022 | 617 | 0.220 |
Why?
|
| Aged | 10 | 2024 | 19078 | 0.220 |
Why?
|
| Clone Cells | 3 | 2021 | 214 | 0.210 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 119 | 0.210 |
Why?
|
| Re-Irradiation | 1 | 2022 | 15 | 0.210 |
Why?
|
| Neoplasm Transplantation | 3 | 2017 | 397 | 0.210 |
Why?
|
| Chromatin | 2 | 2017 | 397 | 0.210 |
Why?
|
| Organoids | 1 | 2022 | 62 | 0.210 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2021 | 282 | 0.210 |
Why?
|
| Gene Silencing | 3 | 2018 | 178 | 0.200 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2023 | 113 | 0.200 |
Why?
|
| Tissue Distribution | 1 | 2022 | 293 | 0.200 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2022 | 93 | 0.200 |
Why?
|
| Receptors, Notch | 1 | 2022 | 123 | 0.200 |
Why?
|
| Cloud Computing | 1 | 2021 | 11 | 0.190 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2021 | 39 | 0.190 |
Why?
|
| Models, Animal | 1 | 2022 | 276 | 0.190 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2021 | 306 | 0.190 |
Why?
|
| Drug Monitoring | 1 | 2022 | 119 | 0.190 |
Why?
|
| Neoadjuvant Therapy | 1 | 2024 | 373 | 0.190 |
Why?
|
| Sarcoma | 1 | 2022 | 220 | 0.190 |
Why?
|
| Proteasome Inhibitors | 1 | 2020 | 52 | 0.180 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2020 | 15 | 0.180 |
Why?
|
| Viral Load | 1 | 2021 | 145 | 0.180 |
Why?
|
| Disease Progression | 2 | 2015 | 1488 | 0.180 |
Why?
|
| Gene Expression Profiling | 5 | 2018 | 1429 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 83 | 0.180 |
Why?
|
| B7-H1 Antigen | 2 | 2019 | 273 | 0.180 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 43 | 0.180 |
Why?
|
| Computational Biology | 2 | 2021 | 542 | 0.180 |
Why?
|
| RNA, Viral | 1 | 2021 | 314 | 0.180 |
Why?
|
| Cohort Studies | 5 | 2018 | 2863 | 0.180 |
Why?
|
| User-Computer Interface | 1 | 2021 | 187 | 0.180 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2019 | 2 | 0.180 |
Why?
|
| Reproducibility of Results | 4 | 2019 | 2752 | 0.170 |
Why?
|
| Serine Endopeptidases | 1 | 2020 | 146 | 0.170 |
Why?
|
| Genetic Heterogeneity | 1 | 2019 | 63 | 0.170 |
Why?
|
| Paclitaxel | 4 | 2024 | 479 | 0.170 |
Why?
|
| Polymerase Chain Reaction | 3 | 2017 | 921 | 0.170 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 645 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2021 | 595 | 0.170 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2019 | 18 | 0.160 |
Why?
|
| Transcriptome | 2 | 2021 | 628 | 0.160 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2020 | 170 | 0.160 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 195 | 0.160 |
Why?
|
| Databases, Genetic | 1 | 2019 | 263 | 0.160 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2020 | 12 | 0.150 |
Why?
|
| Virus Integration | 1 | 2017 | 16 | 0.150 |
Why?
|
| Carboplatin | 3 | 2024 | 304 | 0.150 |
Why?
|
| Prognosis | 6 | 2022 | 3773 | 0.150 |
Why?
|
| Lung Diseases, Obstructive | 1 | 2017 | 19 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2017 | 24 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 261 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2022 | 726 | 0.140 |
Why?
|
| Laryngeal Neoplasms | 1 | 2017 | 89 | 0.140 |
Why?
|
| Estrogen Receptor beta | 1 | 2017 | 25 | 0.140 |
Why?
|
| Cellular Senescence | 1 | 2017 | 103 | 0.140 |
Why?
|
| Mice, SCID | 4 | 2020 | 261 | 0.140 |
Why?
|
| p21-Activated Kinases | 1 | 2016 | 16 | 0.140 |
Why?
|
| Carcinogenesis | 2 | 2022 | 211 | 0.140 |
Why?
|
| Smoke | 1 | 2016 | 27 | 0.140 |
Why?
|
| Gene Fusion | 1 | 2016 | 39 | 0.140 |
Why?
|
| Bone Marrow Cells | 1 | 2017 | 262 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 330 | 0.140 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2016 | 19 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 2020 | 540 | 0.140 |
Why?
|
| Mammary Tumor Virus, Mouse | 3 | 2013 | 64 | 0.130 |
Why?
|
| Immunotherapy | 2 | 2020 | 669 | 0.130 |
Why?
|
| Antibodies | 1 | 2018 | 353 | 0.130 |
Why?
|
| Promoter Regions, Genetic | 2 | 2017 | 956 | 0.130 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2015 | 4 | 0.130 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2016 | 133 | 0.130 |
Why?
|
| Estrogen Receptor alpha | 1 | 2017 | 147 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6777 | 0.130 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2016 | 127 | 0.130 |
Why?
|
| Translocation, Genetic | 1 | 2016 | 266 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 387 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 319 | 0.130 |
Why?
|
| Hyperplasia | 1 | 2015 | 152 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 304 | 0.130 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 529 | 0.130 |
Why?
|
| Patients | 1 | 2016 | 102 | 0.120 |
Why?
|
| RNA Interference | 2 | 2013 | 376 | 0.120 |
Why?
|
| Anticarcinogenic Agents | 2 | 2006 | 73 | 0.120 |
Why?
|
| Protein Interaction Mapping | 2 | 2012 | 82 | 0.120 |
Why?
|
| Pulmonary Fibrosis | 1 | 2016 | 137 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2016 | 254 | 0.120 |
Why?
|
| Species Specificity | 1 | 2016 | 684 | 0.120 |
Why?
|
| Genome, Human | 2 | 2017 | 767 | 0.120 |
Why?
|
| Cell Survival | 2 | 2016 | 982 | 0.120 |
Why?
|
| China | 1 | 2014 | 233 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 200 | 0.120 |
Why?
|
| Quality of Life | 1 | 2022 | 1662 | 0.110 |
Why?
|
| Melanoma | 1 | 2018 | 467 | 0.110 |
Why?
|
| Mitochondria | 1 | 2017 | 553 | 0.110 |
Why?
|
| Organ Specificity | 1 | 2014 | 272 | 0.110 |
Why?
|
| Genetic Vectors | 2 | 2012 | 446 | 0.110 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2012 | 13 | 0.110 |
Why?
|
| Base Pair Mismatch | 1 | 2012 | 27 | 0.110 |
Why?
|
| Urinary Bladder | 1 | 2015 | 246 | 0.110 |
Why?
|
| Cell Movement | 3 | 2015 | 783 | 0.110 |
Why?
|
| Alkylating Agents | 1 | 2012 | 32 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2012 | 30 | 0.110 |
Why?
|
| Enzyme Activation | 1 | 2014 | 698 | 0.110 |
Why?
|
| Genomics | 1 | 2018 | 761 | 0.100 |
Why?
|
| Computer Simulation | 1 | 2016 | 1097 | 0.100 |
Why?
|
| Neoplasm Staging | 4 | 2022 | 2001 | 0.100 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2012 | 283 | 0.100 |
Why?
|
| DNA, Complementary | 1 | 2012 | 392 | 0.100 |
Why?
|
| Arsenic | 1 | 2015 | 256 | 0.100 |
Why?
|
| Algorithms | 2 | 2018 | 1875 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2018 | 763 | 0.100 |
Why?
|
| Cloning, Molecular | 1 | 2012 | 646 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2012 | 213 | 0.100 |
Why?
|
| Transfection | 1 | 2012 | 911 | 0.090 |
Why?
|
| Recombinant Proteins | 1 | 2012 | 1012 | 0.090 |
Why?
|
| Mammary Glands, Animal | 1 | 2010 | 80 | 0.090 |
Why?
|
| Biomarkers | 1 | 2016 | 1755 | 0.090 |
Why?
|
| Thiazoles | 1 | 2010 | 128 | 0.090 |
Why?
|
| Apoptosis | 4 | 2020 | 1717 | 0.090 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2009 | 34 | 0.090 |
Why?
|
| Phenotype | 2 | 2014 | 2439 | 0.080 |
Why?
|
| Tumor Cells, Cultured | 3 | 2020 | 1057 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 3 | 2015 | 306 | 0.080 |
Why?
|
| Tumor Burden | 2 | 2020 | 308 | 0.080 |
Why?
|
| Chemoradiotherapy | 2 | 2022 | 309 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 3211 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 267 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2014 | 667 | 0.080 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2011 | 295 | 0.080 |
Why?
|
| Pyrimidines | 1 | 2010 | 372 | 0.080 |
Why?
|
| Cetuximab | 2 | 2018 | 117 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2007 | 56 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 2362 | 0.070 |
Why?
|
| Breast Neoplasms | 2 | 2018 | 3000 | 0.070 |
Why?
|
| Rosmarinus | 1 | 2006 | 1 | 0.070 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 1 | 2006 | 5 | 0.070 |
Why?
|
| Leukemia, Experimental | 1 | 2006 | 15 | 0.070 |
Why?
|
| Blotting, Western | 3 | 2015 | 794 | 0.070 |
Why?
|
| Cholecalciferol | 1 | 2006 | 35 | 0.070 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 185 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2017 | 1768 | 0.060 |
Why?
|
| ROC Curve | 2 | 2017 | 781 | 0.060 |
Why?
|
| Plant Extracts | 1 | 2006 | 245 | 0.060 |
Why?
|
| Carotenoids | 1 | 2003 | 15 | 0.060 |
Why?
|
| Histone Demethylases | 1 | 2023 | 32 | 0.060 |
Why?
|
| Longevity | 1 | 2023 | 58 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2020 | 1855 | 0.050 |
Why?
|
| Centrioles | 1 | 2022 | 4 | 0.050 |
Why?
|
| Bacteria | 2 | 2023 | 472 | 0.050 |
Why?
|
| Antioxidants | 1 | 2003 | 226 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2020 | 1990 | 0.050 |
Why?
|
| Hydroxyurea | 1 | 2022 | 239 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2022 | 23 | 0.050 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2062 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 129 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 248 | 0.050 |
Why?
|
| 4-Nitroquinoline-1-oxide | 1 | 2021 | 15 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2022 | 8203 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 1 | 2022 | 272 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 98 | 0.050 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 98 | 0.050 |
Why?
|
| Caenorhabditis elegans | 1 | 2023 | 230 | 0.050 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 45 | 0.050 |
Why?
|
| Carcinogens | 1 | 2021 | 111 | 0.050 |
Why?
|
| Cells, Cultured | 2 | 2017 | 2880 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2022 | 4273 | 0.050 |
Why?
|
| Induction Chemotherapy | 1 | 2022 | 151 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 3657 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 57 | 0.050 |
Why?
|
| Bortezomib | 1 | 2020 | 82 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2022 | 561 | 0.050 |
Why?
|
| Biological Availability | 1 | 2020 | 92 | 0.050 |
Why?
|
| DNA Repair | 1 | 2022 | 362 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2020 | 85 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2020 | 14 | 0.040 |
Why?
|
| Oncogene Protein v-akt | 1 | 2020 | 21 | 0.040 |
Why?
|
| Nose Neoplasms | 1 | 2019 | 31 | 0.040 |
Why?
|
| Cyclin D1 | 1 | 2020 | 84 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 198 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2020 | 67 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 779 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2021 | 332 | 0.040 |
Why?
|
| Colon | 1 | 2022 | 509 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 112 | 0.040 |
Why?
|
| Base Sequence | 2 | 2017 | 2327 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2020 | 370 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 682 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 1157 | 0.040 |
Why?
|
| Time Factors | 2 | 2018 | 5320 | 0.040 |
Why?
|
| Aging | 1 | 2023 | 716 | 0.040 |
Why?
|
| Cystadenoma | 1 | 2018 | 19 | 0.040 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 19 | 0.040 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2018 | 20 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 638 | 0.040 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2019 | 170 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2018 | 45 | 0.040 |
Why?
|
| beta Catenin | 1 | 2020 | 266 | 0.040 |
Why?
|
| Peptides | 1 | 2021 | 647 | 0.040 |
Why?
|
| beta-Galactosidase | 1 | 2017 | 73 | 0.040 |
Why?
|
| Risk Factors | 2 | 2021 | 5466 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 66 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2017 | 188 | 0.040 |
Why?
|
| X-Rays | 1 | 2017 | 134 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2018 | 139 | 0.040 |
Why?
|
| CD146 Antigen | 1 | 2017 | 4 | 0.040 |
Why?
|
| Th17 Cells | 1 | 2018 | 84 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2017 | 136 | 0.040 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2017 | 39 | 0.040 |
Why?
|
| Epithelium | 1 | 2018 | 325 | 0.040 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2017 | 21 | 0.040 |
Why?
|
| RNA, Messenger | 2 | 2015 | 2011 | 0.040 |
Why?
|
| Th1 Cells | 1 | 2018 | 166 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2018 | 171 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 131 | 0.040 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2016 | 48 | 0.030 |
Why?
|
| Trabecular Meshwork | 1 | 2016 | 4 | 0.030 |
Why?
|
| Young Adult | 2 | 2022 | 6289 | 0.030 |
Why?
|
| Sclera | 1 | 2016 | 11 | 0.030 |
Why?
|
| Gene Ontology | 1 | 2016 | 34 | 0.030 |
Why?
|
| Aqueous Humor | 1 | 2016 | 24 | 0.030 |
Why?
|
| Optic Nerve | 1 | 2016 | 36 | 0.030 |
Why?
|
| Survival Rate | 1 | 2020 | 1889 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2016 | 96 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 2016 | 57 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2016 | 75 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2016 | 69 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2016 | 337 | 0.030 |
Why?
|
| Tobacco Products | 1 | 2016 | 50 | 0.030 |
Why?
|
| Allelic Imbalance | 1 | 2015 | 22 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2016 | 150 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1837 | 0.030 |
Why?
|
| Proteome | 1 | 2016 | 132 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 1214 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 1796 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 187 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 1108 | 0.030 |
Why?
|
| Fibrosis | 1 | 2016 | 234 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2015 | 208 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2017 | 359 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 557 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 771 | 0.030 |
Why?
|
| Rats | 1 | 2020 | 4041 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 866 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 136 | 0.030 |
Why?
|
| Molecular Targeted Therapy | 1 | 2016 | 285 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 1130 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2015 | 294 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 90 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2013 | 273 | 0.030 |
Why?
|
| Gene Expression Regulation | 2 | 2016 | 1975 | 0.030 |
Why?
|
| Quinazolines | 1 | 2013 | 221 | 0.030 |
Why?
|
| Software | 1 | 2016 | 665 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 2011 | 70 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 967 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 859 | 0.020 |
Why?
|
| CpG Islands | 1 | 2011 | 157 | 0.020 |
Why?
|
| Aurora Kinases | 1 | 2010 | 17 | 0.020 |
Why?
|
| Dasatinib | 1 | 2010 | 37 | 0.020 |
Why?
|
| Azacitidine | 1 | 2011 | 146 | 0.020 |
Why?
|
| src-Family Kinases | 1 | 2010 | 76 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 110 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2010 | 221 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 323 | 0.020 |
Why?
|
| Models, Biological | 1 | 2016 | 1764 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2010 | 426 | 0.020 |
Why?
|
| United States | 1 | 2022 | 6957 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 307 | 0.020 |
Why?
|
| Adolescent | 1 | 2022 | 9237 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 691 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2010 | 509 | 0.020 |
Why?
|
| Transformation, Genetic | 1 | 2007 | 41 | 0.020 |
Why?
|
| DNA, Recombinant | 1 | 2007 | 67 | 0.020 |
Why?
|
| Cell Line | 1 | 2011 | 2495 | 0.020 |
Why?
|
| Gene Library | 1 | 2007 | 133 | 0.020 |
Why?
|
| Polyphenols | 1 | 2006 | 13 | 0.020 |
Why?
|
| Plant Preparations | 1 | 2006 | 21 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 2335 | 0.020 |
Why?
|
| Phenols | 1 | 2006 | 41 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 275 | 0.020 |
Why?
|
| Plasmids | 1 | 2007 | 291 | 0.020 |
Why?
|
| Flavonoids | 1 | 2006 | 87 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 543 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 306 | 0.020 |
Why?
|
| Leukemia, Myeloid | 1 | 2006 | 249 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2006 | 1088 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2007 | 439 | 0.010 |
Why?
|
| Cell Communication | 1 | 2003 | 199 | 0.010 |
Why?
|
| Cell Division | 1 | 2003 | 696 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2006 | 1940 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2007 | 3027 | 0.010 |
Why?
|
| Calcium | 1 | 2006 | 1172 | 0.010 |
Why?
|
| Cell Cycle Proteins | 1 | 2003 | 401 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2015 | 9003 | 0.010 |
Why?
|